- US-listed companies
- BridgeBio Pharma, Inc.
- Income statement
BridgeBio Pharma, Inc.BBIO
Market cap
$14.5B
P/E ratio
| 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 41 | 8 | 70 | 78 | 9 | 222 |
| Revenue growth (%) | - | |||||
| Cost of revenue | - | - | 3 | - | 2 | 4 |
| Research & development | 210 | 337 | 451 | 399 | 456 | 506 |
| Selling, general & administrative | - | - | 192 | 143 | 151 | 289 |
| Operating margin (%) | ||||||
| Operating income | -266 | -474 | -577 | -512 | -607 | -593 |
| Operating expenses | 307 | 483 | 646 | 590 | 617 | 815 |
| Income before tax | - | 505 | - | - | - | -542 |
| Pretax margin (%) | - | 6,127.9 | - | - | - | -244.3 |
| Provision for income taxes | - | - | - | - | - | 1 |
| Effective tax rate (%) | - | - | - | - | - | |
| Net income | -289 | -505 | -586 | -485 | -653 | -543 |
| Net income margin (%) | ||||||
| Earnings per share | - | - | - | -3.26 | -3.95 | -2.88 |
| Diluted EPS | - | - | - | -3.26 | -3.95 | -2.88 |
| EBITDA | - | - | ||||
| EBITDA margin (%) | - | - |